Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Account Payables (2020 - 2024)

Historic Change in Account Payables for Silence Therapeutics (SLN) over the last 5 years, with Q3 2024 value amounting to -$862735.3.

  • Silence Therapeutics' Change in Account Payables fell 82457.14% to -$862735.3 in Q3 2024 from the same period last year, while for Sep 2024 it was $3.2 million, marking a year-over-year increase of 18991.35%. This contributed to the annual value of $54610.7 for FY2023, which is 9695.05% down from last year.
  • As of Q3 2024, Silence Therapeutics' Change in Account Payables stood at -$862735.3, which was down 82457.14% from $5.9 million recorded in Q2 2024.
  • Over the past 5 years, Silence Therapeutics' Change in Account Payables peaked at $5.9 million during Q2 2024, and registered a low of -$4.2 million during Q1 2022.
  • Its 5-year average for Change in Account Payables is $688904.9, with a median of $939551.9 in 2023.
  • Over the last 5 years, Silence Therapeutics' Change in Account Payables had its largest YoY gain of 48142.13% in 2024, and its largest YoY loss of 82457.14% in 2024.
  • Over the past 5 years, Silence Therapeutics' Change in Account Payables (Quarter) stood at $2.9 million in 2020, then crashed by 37.27% to $1.8 million in 2021, then plummeted by 247.3% to -$2.7 million in 2022, then skyrocketed by 134.77% to $939551.9 in 2023, then plummeted by 191.82% to -$862735.3 in 2024.
  • Its last three reported values are -$862735.3 in Q3 2024, $5.9 million for Q2 2024, and -$2.7 million during Q1 2024.